BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36102903)

  • 1. Difelikefalin for pruritus associated with renal disease.
    Manenti L; Fenaroli P
    Drugs Today (Barc); 2022 Sep; 58(9):427-435. PubMed ID: 36102903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis.
    Rastogi A; Fishbane S; Lerma E
    Expert Rev Clin Pharmacol; 2023 May; 16(5):387-400. PubMed ID: 37010031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difelikefalin: A New κ-Opioid Receptor Agonist for the Treatment of Hemodialysis-Dependent Chronic Kidney Disease-Associated Pruritus.
    Fugal J; Serpa SM
    Ann Pharmacother; 2023 Apr; 57(4):480-488. PubMed ID: 35942600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difelikefalin: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1937-1944. PubMed ID: 34674115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous difelikefalin for the treatment of hemodialysis pruritus.
    Mahmoud RH; Mahmoud O; Yosipovitch G
    Expert Rev Clin Immunol; 2024; 20(1):31-37. PubMed ID: 37847514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis.
    Thokala P; Hnynn Si PE; Hernandez Alava M; Sasso A; Schaufler T; Soro M; Fotheringham J
    Pharmacoeconomics; 2023 Apr; 41(4):457-466. PubMed ID: 36735201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease.
    Lipman ZM; Yosipovitch G
    Expert Opin Pharmacother; 2021 Apr; 22(5):549-555. PubMed ID: 33190563
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus.
    Yosipovitch G; Awad A; Spencer RH; Munera C; Menzaghi F
    J Am Acad Dermatol; 2023 Aug; 89(2):261-268. PubMed ID: 37059302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.
    Weiner DE; Schaufler T; McCafferty K; Kalantar-Zadeh K; Germain M; Ruessmann D; Morin I; Menzaghi F; Wen W; Ständer S
    Nephrol Dial Transplant; 2024 Jun; 39(7):1125-1137. PubMed ID: 37968132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Difelikefalin on the Health-Related Quality of Life of Haemodialysis Patients with Moderate-To-Severe Chronic Kidney Disease-Associated Pruritus: A Single-Arm Intervention Trial.
    Fotheringham J; Guest J; Latus J; Lerma E; Morin I; Schaufler T; Soro M; Ständer S; Zeig S
    Patient; 2024 Mar; 17(2):203-213. PubMed ID: 38196014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review.
    Wala K; Szepietowski JC
    Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
    Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F;
    JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study.
    Weiner DE; Vervloet MG; Walpen S; Schaufler T; Munera C; Menzaghi F; Wen W; Bhaduri S; Germain MJ;
    Kidney Med; 2022 Oct; 4(10):100542. PubMed ID: 36185706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2.
    Fishbane S; Clegg DJ; Lerma EV; Rastogi A; Budden J; Morin I; Wen W; Menzaghi F; Topf J
    Am J Nephrol; 2024; 55(3):329-333. PubMed ID: 38253036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
    Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F;
    N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difelikefalin for Hemodialysis Patients with Pruritus in Japan.
    Narita I; Tsubakihara Y; Takahashi N; Ebata T; Uchiyama T; Marumo M; Okamura S; Gejyo F;
    NEJM Evid; 2023 Nov; 2(11):EVIDoa2300094. PubMed ID: 38320524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of difelikefalin in the treatment of hemodialysis patients with pruritus: A meta-analysis and systematic review.
    Xue G; Yuan H; Fan D; Yang Y; Ma C; Liu J; Liao R
    Clin Nephrol; 2024 Apr; 101(4):155-163. PubMed ID: 38294219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Difelikefalin and treatment of severe pruritus associated with chronic kidney disease - Real-life retrospective study in a dialysis center].
    Brasme R; Cartery C; Goubet M; Hennino MF; Maisonneuve N
    Nephrol Ther; 2024 Jun; 20(3):1-9. PubMed ID: 38874419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis and management of pruritus associated with chronic kidney disease in hemodialyzed patients].
    Lanot A; Misery L; Rostoker G; Testa A; Chauveau P; Touzot M; Florens N; Bataille P
    Nephrol Ther; 2024 Feb; 20(1):50-60. PubMed ID: 38294264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies.
    Topf J; Wooldridge T; McCafferty K; Schömig M; Csiky B; Zwiech R; Wen W; Bhaduri S; Munera C; Lin R; Jebara A; Cirulli J; Menzaghi F
    Kidney Med; 2022 Aug; 4(8):100512. PubMed ID: 36016762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.